 Darunavirritonavir is one of the preferred antiretroviral agents as part of combination antiretroviral therapy for treatment of HIV-infected adults according to international guidelines. For children 3-12 years old, FDA has approved once daily dosing of darunavirritonavir. Dosing recommendations for children 6-12 years old have been approved based on a modelling and simulation procedure by the company. 